

UNITED STATES ARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR			ATTORNEY DOCKET NO.
09/519,72	8 03/03/0	0 WEINTRAUB		В	UOFMD.002C1
-			\neg	EXAMINER	
020995		HM12/0705	•		
KNOBBE MARTENS OLSON & BEAR LLP				LAZAR WESLEY,E	
620 NEWPORT CENTER DRIVE				ART UNIT	PAPER NUMBER
SIXTEENTH	FLOOR				7
NEWPORT BEACH CA 92660				1646	7
				DATE MAILED:	
					07/05/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Application No. App

09/519,728

Applicant(s)

Weintraub

Examiner

Office Action Summary

Eliane Lazar-Wesley

Art Unit



		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
	The MAILING DATE of this communication appears	s on the cover sheet with the corres	pondence address			
	for Reply					
ITTE	IORTENED STATUTORY PERIOD FOR REPLY IS SE MAILING DATE OF THIS COMMUNICATION.					
u,	nsions of time may be available under the provisions of 37 (fter SIX (6) MONTHS from the mailing date of this communi e period for reply specified above is less than thirty (30) day	Cation				
- If NO	Deriod for reply is specified above, the maximum statutory					
- Failu - Any	ommunication. re to reply within the set or extended period for reply will, b reply received by the Office later than three months after th arned patent term adjustment. See 37 CFR 1.704(b).	V statute, cause the smallestick at				
Status	,					
1)	Responsive to communication(s) filed on					
2a) 🗌		tion is non-final.				
3) □	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposi	tion of Claims					
4) 💢	Claim(s) <u>1-66</u>	is/are	pending in the application.			
4	a) Of the above, claim(s)	is/are	withdrawn from consideration.			
5) 🗌	Claim(s)	i:	s/are allowed.			
6) 🗆	Claim(s)					
7) 🗌	Claim(s)	i	s/are objected to.			
8) 💢	Claims <u>1-66</u>	are subject to restrict	ion and/or election requirement.			
	tion Papers		- 4			
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	objected to by the Examiner.				
11)	The proposed drawing correction filed on		disapproved.			
12) <u></u>	The oath or declaration is objected to by the Exami	ner.	, == usapprovou.			
Priority (under 35 U.S.C. § 119					
13)□	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(a	d).			
a) 🗌						
1	. \square Certified copies of the priority documents have	e been received.				
2	C. Certified copies of the priority documents have					
	Copies of the certified copies of the priority do application from the International Burea	ocuments have been received in the property (PCT Rule 17, 2(a))	nis National Stage			
36 141□	e the attached detailed Office action for a list of the	certified copies not received.				
	Acknowledgement is made of a claim for domestic	priority under 35 U.S.C. § 119(e)				
ttachmei						
		18) Interview Summary (PTO-413) Paper No	-			
		19) Notice of Informal Patent Application (PT	O-152)			
·/ [1/10	Paper No(s).	20) Other:	<u>†</u>			

Application/Control Number: 09/519,728

Art Unit: 1646

DETAILED ACTION

Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-12 and 41, drawn to a mutant alpha subunit, classified in class 540, subclass350.
 - II. Claims 13-25, and 57, 60, 63, 64, 66, drawn to a mutant TSH heterodimer, compositions and a kit, classified in class 530, subclass 397.
 - III. Claims 26-31, 39, and 58, 61, 62, 63, 64, 66, drawn to a mutant TSH heterodimer wherein at least the beta or the alpha subunit contains a substitution, compositions and a kit, classified in class 530, subclass 397.
 - IV. Claims 32-38, 40, 42, 59, 63, 64, 65, 66, drawn to a TSH analog wherein the subunits are covalently bound, classified in class 530, subclass 397.
 - V. Claim 43, drawn to a method of treating or preventing hypothyroidism by administering mutant TSH heterodimer, classified in class 514, subclass 8.
 - VI. Claim 44, drawn to a method of treating or preventing hypothyroidism by administering TSH analog, classified in class 514, subclass 8.
 - VII. Claims 45, 46, drawn to a method of treating thyroid cancer by administering mutant TSH heterodimer, classified in class 514, subclass 8.

Art Unit: 1646

- VIII. Claim 47, drawn to a method of diagnosing thyroid cancer, by administering mutant TSH heterodimer, classified in class 514 subclass 8.
- IX. Claim 48, drawn to a method of diagnosing thyroid cancer, by administering mutant TSH, classified in class 514 subclass 8.
- Claim 49, drawn to a method of diagnosing thyroid cancer, by administering mutant
 TSH heterodimer, classified in class 514 subclass 8.
- XI. Claims 50, 51, drawn to a method of diagnosing thyroid cancer, by administering TSH analog, classified in class 514 subclass 8.
- XII. Claim 52, drawn to a method of diagnosing thyroid cancer, by administering TSH analog, classified in class 514 subclass 8.
- XIII. Claims 53, 54, drawn to a method of diagnosing or screening for disorder characterized by the presence of antibodies against TSH receptor, using TSH heterodimer, classified in class 435 subclass 7.1.
- XIV. Claims 55, 56, drawn to a method of diagnosing or screening for disorder characterized by the presence of antibodies against TSH receptor, using TSH analog, classified in class 435 subclass 7.1.
- 2. The inventions are distinct, each from the other because of the following reasons:

The products of Inventions I-IV are independent and distinct, as they differ structurally and functionnally.

Art Unit: 1646

The products of Inventions I-IV, and the methods of Inventions V-XIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process of using the compositions can be practiced with other substances, and the products can be used to make antibodies.

The methods of Claims V-XIII are independent and distinct, as they use different reagents and method steps, and reach different goals.

Because these inventions are distinct for the reasons given above and have acquired a separate 3. status in the art as shown by their different subject matter and the necessity for non-coextensive literature searches, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner 4. should be directed to Eliane Lazar-Wesley, PhD, whose telephone number is (703) 305 4059. The examiner can normally be reached on Monday-Friday from 9:30am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564.

Art Unit: 1646

Official papers filed by fax should be directed to (703) 308 4242. Faxed draft or informal communications with the examiner should be directed to (703) 308-0294.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ELW

July 02, 2001

EW

CHRISTINE J. SAOUD PRIMARY EXAMINER